Efficacy of enteral decontamination in the prevention of anastomotic dehiscence and pulmonary infection in esophagogastric surgery.
Our aim in this study is to evaluate the efficacy of decontamination of the high digestive tract in reducing the incidence of anastomotic dehiscence, pulmonary infection and mortality after resective gastro-esophageal surgery. A prospective randomized and double-blinded study was conducted in patients undergoing total gastrectomy for gastric cancer and esophagectomy for esophageal cancer. Two groups were studied: group A patients were given erythromycin + gentamicine + nistatine sulfate orally; group B patients were given placebo. Mortality, incidence of anastomotic dehiscence and incidence of pulmonary infection were the end points evaluated. One hundred and nine consecutive patients were randomized. Eighteen (16.5%) were excluded. From the 91 patients who were evaluated, 42 (46.2%) received an esophagectomy and 49 (53.8%) had a total gastrectomy. Esophagectomies showed: a 0% rate of anastomotic dehiscence in group A and 12.5% in group B, P = 0.176; a pulmonary infection rate of 22.2% in group A and 29.1% in group B, P = 0.443; and mortality rate was 0% in group A and 12.5% in group B, P = 0.176. After gastrectomy, anastomotic dehiscence rate was 4.5% in group A and 0% in group B, P = 0.449; pulmonary infection rate was 4.5% in group A and 11.1% in group B, P = 0.387 and mortality was 9% in group A and 0% in group B, P = 0.196. Decontamination protocol does not help in decreasing the incidence of anastomotic dehiscence, pulmonary infection and mortality in the present study. Nevertheless, there seems to be a tendency to low pulmonary infection after gastrectomy and esophagectomy and to improve the incidence of anastomotic dehiscence after esophagectomy. Further studies are needed to re-evaluate these findings.
Farran
L
L
Surgery, Hospital Universitari de Bellvitge, Barcelona, Spain. lfarran@aecirujanos.es
Llop
J
J
Sans
M
M
Kreisler
E
E
Miró
M
M
Galan
M
M
Rafecas
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000714:Anastomosis, Surgical; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D003666:Decontamination; D004311:Double-Blind Method; D004917:Erythromycin / Q000627:therapeutic use*; D016629:Esophagectomy; D004947:Esophagus / Q000601:surgery*; D005260:Female; D005743:Gastrectomy; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009761:Nystatin / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000517:prevention & control*; D011300:Preoperative Care; D011446:Prospective Studies; D013270:Stomach / Q000601:surgery*; D013529:Surgical Wound Dehiscence / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D009761:Nystatin; D004917:Erythromycin